Diagnosis and management of porphyria

British Medical Journal

Volumn 320, Issue 7250, 2000, Pages 1647-1651

  Thadani, Helen ^a   Deacon, Allan ^b   Peters, Timothy ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CAROTENE; CHLORAMPHENICOL DERIVATIVE; DANAZOL; DIAZEPAM DERIVATIVE; ESTROGEN; METHYLDOPA; PHENYTOIN DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; TETRACYCLINE DERIVATIVE;

HEME SYNTHESIS; HUMAN; PORPHYRIA; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; GENETIC SCREENING; HUMANS; PORPHYRIA CUTANEA TARDA; PORPHYRIAS;

EID: 0034679250     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. 1 Elder GH, Smith SG, Jane Smyth S. Laboratory investigation of the Porphyrias. Ann Clin Biochem 1990;27:395-412.
2. 2 Kappas A, Sassa S, Galbraith RA, Nardaman Y. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited diseases. 6th ed. New York: McGraw-Hill, 1989:1305-66.
3. 3 Thadani H, Wassif W, Deacon A, Peters T. Neuropsychiatric manifestations of acute intermittent porphyria. J Psychiatric Case Reports 1997;2: 29-35.
4. 4 Elder GH, Hift RT, Meissner PN. The acute porphyrias. Lancet 1997;349:1613-7.
5. 5 Monterio H, Bechara EJH, Abdalla DSP. Free radicals involvement in neurological porphyrias and lead poisoning. Mol Cell Biochem 1991;103:73-84.
6. 6 Bonkovsky HL. Advances in understanding and treating "the little imitator", acute porphyria. Gastroenterology 1993:105:590-4.
7. 7 Lindberg RLP, Parcher C, Grandchamp B. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet 1996;12:195-9.
8. 8 De Verneuilh, GC, Boulechfar S, Moreau-Gaudry F. Porphyrias: animal models and prospects for cellular and gene therapy. J Bioenerg Biomed 1995;27:239-48.
9. 9 Meyer UA, Schuurmans MM, Lindberg RL. A review of the pathogenesis of the neurological manifestations of the acute porphyrias. Seminars in Liver Disease 1998;18:43-52.
10. 10 Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992;71:1-13.
11. 11 McColl KEL, Dover S, Fitzsimons E, Moore MR. Porphyrin metabolism and the porphyrias. In: Weatherall DJ. Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine. Oxford: Oxford University Press, 1996: 1388-99.
12. 12 Lip GYH, McColl KEL, Goldberg A, Moore RA. Smoking and recurrent attacks of acute intermittent porphyria. BMJ 1991;302:507-8.
13. 13 Disler PB, Moore MR. Drug-sensitive diseases: Acute porphyrias. Adverse Drug Reaction Bulletin 1989;129:484-7.
14. 14 Buttery JE. Is the Watson-Schwartz screening method for porphobilinogen reliable? Clin Chem 1995;41:1670-1.
15. 15 Deacon AC, Peters TJ. Identification of acute porpryria: equation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem 1998;35:726-32.
16. 16 Poh-Fitzpatick MB. A plasma fluorescence marker for variegate porphyria. Arch Dermatol 1980;116:543-7.
17. 17 Long C, Smyth SJS, Woolf J. Murphy GM. Detection of latent variegate porphyria by fluorescence. Br J Dermatol 1993;129:9-13.
18. 18 Bonkowsky HL, Sinclair PR, Scott E, Sinclair JF. Seizure management in acute hepatic porphyria: risks of valporate and clonazepam. Neurology 1980;30:588-92.
19. 19 Birchfield RI, Cowger ML. Acute intermittent porphyria with seizures. Anticonvulsant medication - induced metabolic changes. Am J Dis Child 1966;112:561-5.
20. 20 Magnussen CR, Doherty JM, Hess RA, Tschudy DP. Grand mal seizures and acute intermittent porphyria. The problem of differential diagnosis and treatment. Neurology 1975;25:121-5.
21. 21 Hahn M, Gildemeister OS, Krauss GL, Pepe JA, Lambrecht RW, Donohue S, et al. Effects of new anticonvulsant medications on porphyrin in cultured liver cells: potential implications for patients with acute porphyria. Neurology 1997;49:97-106.
22. 22 Tatum WO 4th, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995;45:1216-7.
23. 23 Krauss GL, Simmons-O'Brien E, Campbell M. Successful treatment of seizures and porphyria with gabapentin. Neurology 1995;45(part 1):594-5.
24. 24 Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyria attacks. Arch Intern Med 1993;153:2004-8.
25. 25 Dover SB, Moore MR, Fitzsimmons EJ, Graham A, McCall KE. Tin protoporphyria prolongs the biochemical remission produced by heme arginate in acute hepatic porphyria. Gastroenterology 1993;105:500-6.
26. 26 Brodie MJ, Moore MR, Thompson GG, Goldberg A, Low RAL. Pregnancy and the acute porphyria. Br J Obstet Gynaecol 1977;84:726-31.
27. 27 Todd DJ. Erythropoietic protoporphyria. Br J Dermatol 1994;131:751-66.
28. 28 Fritsch C, Bolsen K, Ruzicka T, Goerz G. Congenital erythropoietic porphyria. J Am Acad Dermatol 1997;36:594-610.
29. 29 Elder GH, Worwood M. Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload. Hepatology 1998;289-90.
30. 30 Elder GH. Porphyria cutanea tarda: a multifactorial disease. In: Champion RH, Pye RJ eds. Recent advances in dermatology. No 8. Edinbrugh: Churchill Livingstone, 1990:55-70.
31. 31 Bengtsson NO, Hardell L. Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer 1986;54:115-7.
32. 32 Elden GH. Porphyria cutanea tarda. Seminars in Liver Disease 1998;18(I):67-75.
33. 33 Ashton RE, Hawk JLM, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol 1981;111:609-13.
34. 34 Kordac V, Jirsa M, Kotal P. Agents affecting porphyrin formation and secretion: implications for porphyria cutanea tarda. Semin Hematol 1989;26:16-23.
35. 35 Mathews-Roth MM. Carotenoids in erythropoietic proto-porphyria and other photosensitive diseases. Ann N Y Acad Sci 1993;691:127-38.
36. 36 Lee JD, Anvert M. Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with AIP. Proc Nat Acad Sci U S A 1991;88:10912-5.